A RANDOMIZED CASE–CONTROL PILOT STUDY ON THE NEUROCHEMICAL BASIS OF PAIN MODULATION IN PATIENTS WITH MIGRAINE, WHO PRACTICED INTEGRATED AMRITA MEDITATION TECHNIQUE

VANDANA BALAKRISHNAN; ANAND KUMAR; ARYALAKSHMI CS; MRUDULA M; RENJU RAJAN; GREESHMA C RAVINDRAN

doi:10.22159/ajpcr.2022.v15i4.44173

Authors

VANDANA BALAKRISHNAN Department of Physiology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.
ANAND KUMAR Department of Neurology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.
ARYALAKSHMI CS Department of Physiology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.
MRUDULA M Department of Physiology, Amrita Institute of Medical Sciences, Kochi, Kerala, India. https://orcid.org/0000-0001-5565-0498
RENJU RAJAN Department of Physiology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.
GREESHMA C RAVINDRAN Department of Statistics, Amrita Institute of Medical Sciences, Kochi, Kerala, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i4.44173

Keywords:

Headache, migraine, yoga, meditation, neurotransmitters, IAM

Abstract

Objective: The objective of the study was to determine the changes in duration and intensity of headache and associated changes in the plasma levels of neurochemicals, serotonin, glutamate, vasoactive intestinal peptide (VIP), and nitric oxide (NO) in patients with migraine after 6 months of regular practice of integrated Amrita meditation (IAM).

Methods: Sixteen patients aged 18–50 with migraine were randomly assigned to 2 groups, one with standard medical care and IAM, and the other only standard medical care. Data were collected before IAM, after 3 and 6 months of IAM practice

Results: After 6 months, a significant decrease in the duration of headache from 2.4±0.54 to 1.4±0.54 (p=0.034) hours and intensity of pain from 3.6±0.54 to 2.6±0.89, (p=0.035) was seen in patients who practiced IAM. Plasma levels of serotonin within the IAM group increased (47.29±26.85 to 53.85±29.73ng/ml), where as there was decrease in glutamate (38.47±8.2 to 29.68±12.57μg/ml), VIP (28.01±13.64 to 22.23±7.79pg/ml) and NO levels (642.26±167.42 to 423.18±97.96μmol/L). A correlating trend was seen in comparison with control group after 6 months showing a statistically significant difference in plasma Serotonin (p value 0.007) and NO (p value-0.023) levels.

Discussion: The results of our study have been discussed with other migraine and meditation-related studies.

Conclusion: Regular practice of IAM reduces the intensity and duration of headache in migraine patients and is associated with alterations in the neurotransmitter levels.

Downloads

Download data is not yet available.

References

Mamindla P, Mogilicherla S, Enumula D, Prasad OP, Anchuri SS. Review on migraine. Acta Sci Pharm Sci 2019;3:29-42.

Sahithi AS, Muthy T, Migraine SR. Update and future perspectives. Int J Nutr Pharmacol Neurol Dis 2020;10:179-87.

Wachholtz AB, Malone CD, Pargament KI. Effect of different meditation types on migraine headache medication use. Behav Med 2017;43:1-8. doi: 10.1080/08964289.2015.1024601, PMID 25864906

Kakigi R, Nakata H, Inui K, Hiroe N, Nagata O, Honda M, et al. Intracerebral pain processing in a Yoga Master who claims not to feel pain during meditation. Eur J Pain 2005;9:581-9. doi: 10.1016/j. ejpain.2004.12.006, PMID 16139187

Boyles S. Migraine Drugs’ Effects Scare Many Away. United States: WebMD Arch; 2003. doi: 10.1111/j.1468-2982.2004.00750.x, PMID 15315529

Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol 2021;17:501-14. doi: 10.1001/ jamanetworkopen.2021.18543, PMID 34357396

Diener HC, Holle-Lee D, Nägel S, Dresler T, Gaul C, Göbel H, et al. Treatment of migraine attacks and prevention of migraine: Guidelines by the german migraine and headache society and the German society of neurology. Clin Transl Neurosci 2019;3:77. doi: 10.1007/ s101940070036

Woodyard C. Exploring the therapeutic effects of yoga and its ability to increase quality of life. Int J Yoga 2011;4:49-54.

Sarika KS, Balakrishnan V, Sundaram KR, Kumar H. The effect of integrated amrita meditation (IAM) technique on glycemic control in type 2 diabetes. Int J Physiol 2019;7:218-23. doi: 10.1089/ acm.2020.0238

Montes LL, Balakrishnan V, Suja G. Effects of integrated amrita meditation technique on anxiety, depression, and plasma neurotransmitters on a healthy population: A randomized controlled trial followed by a case-control study. J Altern Complement Med 2021;27:641-8. doi: 10.4103/ijmr.IJMR_2109_18, PMID 33707393

Sarika KS, Kumar H, Balakrishnan V, Sundaram KR. Impact of integrated amrita meditation technique on stress in type 2 diabetic patients. Indian J Med Res 2020;152:508-14.

Peres MF, Zukerman E, Soares CA, Alonso EO, Santos BF, Faulhaber MH. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 2004;24:735-9. doi: 10.1038/s41582-021- 00509-5, PMID 34145431

Pellesi L, Al-Karagholi MA, De Icco R, Coskun H, Elbahi FA, Lopez-Lopez C, et al. Effect of vasoactive intestinal polypeptide on development of migraine headaches: A randomized clinical trial. JAMA Netw Open 2021;4:e2118543. doi: 10.4103/0973-6131.85485, PMID 22022122

Gallai V, Sarchielli P. Nitric oxide in primary headaches. J Headache Pain 2000;1:145-54. doi: 10.1177/2514183X18823377

Wells RE, O’Connell N, Pierce CR, Estave P, Penzien DB, Loder E, et al. Effectiveness of mindfulness meditation vs headache education for adults with migraine: A randomized clinical trial. JAMA Intern Med 2021;181:317-28. doi: 10.1001/jamainternmed.2020.7090

Krans B. Using yoga to relieve the symptoms of depression. United States: Healthline; 2018.

Streeter CC, Whitfield TH, Owen L, Rein T, Karri SK, Yakhkind A, et al. Effects of yoga versus walking on mood, anxiety, and brain GABA levels: A randomized controlled MRS study. J Altern Complement Med 2010;16:1145-52. doi: 10.1089/acm.2010.0007, PMID 20722471